New products: Repatha (evolocumab) SureClick and PFS -

New products: Repatha (evolocumab) SureClick and PFS
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Cardiovascular system disorders
Summary
The human IgG2 monoclonal antibody evolocumab is licensed for the treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia, and adults and adolescents aged ≥12 years with homozygous familial hypercholesterolaemia.
UKMi comment
Two formulations are available – a prefilled pen (SureClick) and a prefilled syringe (PFS). Both are for single-use only, and are intended for patient self-administration after proper training.
Related links: